Answers are grounded in this paper and cite their sources.
The Intermedics Intertach 262-12 antitachycardia pulse generator demonstrated an 81% clinical success rate in terminating recurrent tachycardias in patients unresponsive to antiarrhythmic drugs.
An antitachycardia pulse generator, the Intermedics Intertach 262-12 was implanted in 16 patients (14 patients with supraventricular tachycardia of various origins and two patients with recurrent ventricular tachycardia), who were not responsive to various antiarrhythmic drug regimens. The follow-up was from 6-49 months (mean 30.9 +/- 13.8). Five patients had a follow-up of over 3 years. The device was used in all patients. One patient with ventricular tachycardia died from a nonarrhythmic cause. Loss of responsiveness to burst pacing was observed in 1/14 patients with supraventricular tachycardia and nontolerance of antitachycardia pacing in one patient. Overall clinical success of pacing was observed in 13/16 patients = 81%. The pacemaker proved to be a versatile system with reliable tachycardia detection and termination functions.
No takes yet. Share an insight, caveat, or question.
Fromer et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: